BofA Securities analyst Alec Stranahan maintains $Intellia Therapeutics (NTLA.US)$ with a buy rating, and adjusts the target price from $65 to $50.
According to TipRanks data, the analyst has a success rate of 42.3% and a total average return of -7.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
Despite ongoing uncertainties related to politics and rates, the overall condition of the Biopharma sector is seen as significantly enhanced compared to its 2022 lows. Furthermore, there's a favorable view towards stocks involved in late-stage clinical trials or those in the early launch phase. Yet, there's growing interest among investors towards Phase 1 clinical programs that present derisking data and near-term catalysts.
The fourth quarter is expected to be generally solid for large and mid-cap commercial stage companies in the Biotech sector, supported by seasonal tailwinds. However, the expectations for 2025 might be overly optimistic, with several product launches already factored into valuations and the sustainability of key franchises posing potential challenges.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Alec Stranahan維持$Intellia Therapeutics (NTLA.US)$買入評級，並將目標價從65美元下調至50美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.3%，總平均回報率為-7.1%。
此外，綜合報道，$Intellia Therapeutics (NTLA.US)$近期主要分析師觀點如下：
儘管與政治和利率相關的不確定性持續存在，但與2022年的低點相比，生物製藥行業的整體狀況被視爲顯著改善。此外，人們對參與後期臨牀試驗或處於早期啓動階段的股票持積極看法。然而，投資者對提供去風險數據和短期催化劑的1期臨牀項目的興趣與日俱增。
在季節性利好風的支持下，生物技術領域的大型和中型商業舞臺公司預計第四季度將總體保持穩健。但是，對2025年的預期可能過於樂觀，一些產品的發佈已經計入了估值，關鍵特許經營權的可持續性構成了潛在的挑戰。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
